Regeneron Pharmaceuticals (REGN) Q3 2026 Earnings Call: Guidance and Outlook
Management provided modest refinements to 2026 financial guidance and offered preliminary outlook commentary for 2027, including expected increases in R&D spending.
About Regeneron Pharmaceuticals. Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses.
Sequential physician unit demand growth of approximately 10%, partially offset by ongoing pricing pressure.
EYLEA Fourth Quarter Demand
Sequential demand decline in the low to mid-teens in the fourth quarter.
Annual guidance
EYLEA HD Full Year Net Sales
Full year net sales growth of over 50% compared with 2025.
2027 R&D Expense
Expected to increase by a mid-teens percentage compared with 2026.
2027 Effective Tax Rate
Expected approximately 100 to 200 basis points of upward pressure relative to 2026.
Share Repurchases
Full year share repurchases expected to total approximately $3 billion.
Outlook
Pipeline progression
Regeneron is on pace to initiate more than 15 Phase III trials in 2026, advancing multiple large registrational programs in myeloma, anticoagulation, obesity, and emerging mid-stage opportunities.
Sanofi collaboration economics
Under the amended antibody collaboration, Regeneron expects to record the full $1 billion upfront payment as Sanofi collaboration revenue in the fourth quarter of 2026.
Inmazeb BARDA supply
Beginning in late 2027, Regeneron expects to supply additional treatment doses of Inmazeb to the U.S. government through 2031, with no revenue anticipated in the fourth quarter of 2026.
Retinal franchise positioning
The retinal franchise remains in a strong position despite increasing competition from Aflibercept 2-mg biosimilar launches, supported by EYLEA HD adoption and the anticipated prefilled syringe.
Dombey's summary of the Regeneron Pharmaceuticals Q3 2026 earnings call held Oct 30, 2026, written from the call itself. Every figure on this page was checked against what was said on the call, and quoted lines are management's own words; we do not add estimates or prices. The tone score is our read of management's wording, guidance and answers. Check figures against the company's SEC filings before acting. This is research, not investment advice.
